Page last updated: 2024-10-27

flecainide and Alloxan Diabetes

flecainide has been researched along with Alloxan Diabetes in 1 studies

Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).

Research Excerpts

ExcerptRelevanceReference
"We designed the present study to examine whether diabetes mellitus affects the antiarrhythmic effect of flecainide, a sodium channel blocker, E-4031, a potassium channel blocker, and verapamil, a calcium channel blocker, in diabetic rats."3.73Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers. ( Hayashi, Y; Ito, I; Iwasaki, M; Kamibayashi, T; Kawai, Y; Mashimo, T; Takada, K; Yamatodani, A, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ito, I1
Hayashi, Y1
Kawai, Y1
Iwasaki, M1
Takada, K1
Kamibayashi, T1
Yamatodani, A1
Mashimo, T1

Other Studies

1 other study available for flecainide and Alloxan Diabetes

ArticleYear
Diabetes mellitus reduces the antiarrhythmic effect of ion channel blockers.
    Anesthesia and analgesia, 2006, Volume: 103, Issue:3

    Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Diabetes Mellitus; Diabetes M

2006